(NP (NP-COOD (NP (NNS Glucocorticoids)) (CC and) (NP (NN interferon-alpha))) (PP (IN in) (NP (DT the) (VBN acquired) (NN immunodeficiency) (NN syndrome))) (. .))
(S (NP-SBJ (NP (DT Some) (NNS patients)) (PP (IN with) (NP (NP (VBN acquired) (NN immunodeficiency) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN AIDS)) (-RRB- -RRB-))))) (VP (VBP develop) (NP (NP (NN glucocorticoid) (NN resistance)) (VP (VBN characterized) (NP (-NONE- *)) (PP (IN by) (NP-LGS-COOD (NP (NP (JJ low) (NP (NP (NN receptor) (NN affinity)) (PRN (-LRB- -LRB-) (NP (NN Kd)) (-RRB- -RRB-)))) (PP (IN for) (NP (NNS glucocorticoids))) (PP (IN in) (NP (JJ mononuclear) (, ,) (NNS cells)))) (CC and) (NP (NP (JJ high) (NNS values)) (PP (IN of) (NP-COOD (NP (NN ACTH)) (CC and) (NP (NN cortisol)))))))))) (. .))
(S (SBAR (IN As) (S (NP-SBJ (NNS glucocorticoids)) (VP (VBP regulate) (NP (NP (NP (NN interferon-alpha)) (PRN (-LRB- -LRB-) (NP (NN IFN) (NN alpha)) (-RRB- -RRB-))) (NN production))))) (, ,) (NP-SBJ-54 (PRP we)) (VP (VBD hypothesized) (SBAR (IN that) (S (NP-SBJ-55 (NP (NN IFN) (NN alpha)) (, ,) (NP (NP (DT a) (NN cytokine)) (VP (VBN produced) (NP (-NONE- *)) (PP (RB predominantly) (IN by) (NP-LGS (NNS monocytes))) (PP (IN in) (NP (NN AIDS))))) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN increased) (NP (-NONE- *-55)) (PP (IN in) (NP (JJ cortisol-resistant) (NN AIDS)))))))) (, ,) (S (NP-SBJ (-NONE- *-54)) (VP (VBG attributing) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NN cortisol) (NN inhibition)))) (PP (TO to) (NP (NN IFN) (NN alpha) (NN production)))))) (. .))
(S (ADVP (RB Therefore)) (, ,) (NP-SBJ (PRP we)) (VP-COOD (VP (VBD examined) (NP (NP (NN glucocorticoid) (NN receptor) (NNS characteristics)) (PP (IN on) (NP (NNS monocytes)))) (PP (IN by) (NP (NN -LCB-3H-RCB-dexamethasone) (NN binding)))) (CC and) (VP (VBD measured) (NP (NP-COOD (NP (NN IFN) (NN alpha)) (, ,) (NP (NN cortisol)) (, ,) (CC and) (NP (NN ACTH))) (PP (IN in) (NP-COOD (NP (NP-COOD (NP (NP (NP (NN AIDS) (NNS patients)) (PP-57 (IN with) (NP (-NONE- *RNR*-56)))) (PRN-58 (-LRB- -LRB-) (NP (NN AIDS-GR)) (-RRB- -RRB-))) (CC or) (NP (PP=57 (IN without) (NP (-NONE- *RNR*-56))) (PRN=58 (-NONE- *ICH*-59)))) (NP-56 (NN glucocorticoid) (NN resistance)) (PRN-59 (-LRB- -LRB-) (NP (NN AIDS-C)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NN C)) (-RRB- -RRB-)))))))) (. .))
(S (NP-SBJ (NP (NNS Monocytes)) (PP (IN of) (NP (NN AIDS-GR) (NNS patients)))) (VP (VBD had) (NP (NP (DT a) (NN receptor) (NN Kd)) (PP (IN of) (NP (QP (CD 10.5) (CC (- +)) (CD 4.2)) (NN (L nmol)))) (SBAR (WHNP-60 (WDT that)) (S (NP-SBJ (-NONE- *T*-60)) (VP (VBD was) (ADJP-PRD (ADJP (JJR higher)) (PP (IN than) (NP (NP-COOD (NP (NP (NP (DT that)) (PP (IN in) (NP-62 (DT the) (NN AIDS-C) (NN group)))) (-LRB- -LRB-) (NP-65 (QP (CD 2.9) (CC (- +)) (CD 0.8)) (NN (L nmol))) (-RRB- -RRB-)) (CC and) (NP (NP=62 (JJ normal) (NNS subjects)) (-LRB- -LRB-) (NP=65 (QP (CD 2.0) (CC (- +)) (CD 0.8)) (NN (L nmol))))) (: ;) (PRN (S (NP-SBJ (NN P)) (ADJP-PRD (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-))))))))) (. .))
(S (NP-SBJ-64 (NN IFN) (NN alpha) (NNS levels)) (VP (VBD were) (VP (VBN increased) (NP (-NONE- *-64)) (PP (IN in) (NP (DT the) (NN AIDS-GR) (NN group))) (PRN (-LRB- -LRB-) (NP-COOD (NP (QP (CD 17) (CC (- +)) (CD 6))) (CC vs.) (NP-COOD (NP (NP (QP (CD 4) (CC (- +)) (CD 1)) (NN (mL U))) (PP (IN in) (NP (DT the) (NN AIDS-C) (NN group)))) (CC and) (NP (NP (QP (CD 2) (CC (- +)) (CD 0.5)) (NN (mL U))) (PP (IN in) (NP (DT the) (NN C) (NN group)))))) (: ;) (S (NP-SBJ (NN P)) (ADJP-PRD (JJR &lt;) (CD 0.01))) (-RRB- -RRB-)))) (. .))
(S (NP-SBJ-63 (NNS Correlations)) (VP (VBD were) (VP (VBN found) (NP (-NONE- *-63)) (PP-COOD (PP (IN between) (NP (NP-COOD (NP (NN plasma) (NN IFN) (NN alpha)) (CC and) (NP (NN receptor) (NN Kd))) (PP (IN on) (NP (NP (NNS monocytes)) (PP (IN of) (NP (NN AIDS-GR))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN r)) (VP (JJ =) (NP-PRD (CD 0.77)))) (-RRB- -RRB-)))) (CC and) (PP (IN between) (NP (NP-COOD (NP (NN IFN) (NN alpha)) (CC and) (NP (NN plasma) (NN cortisol))) (PP (IN in) (NP (DT the) (JJ same) (NN group))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN r)) (VP (JJ =) (NP-PRD (CD 0.74)))) (-RRB- -RRB-))))))) (. .))
(S (S (NP-SBJ-66 (NP (DT The) (JJ poly-LRB-I-RRB--poly-LRB-C-RRB--induced) (NN IFN) (NN alpha) (NN production)) (PP (IN by) (NP (NNS monocytes)))) (VP (VBD was) (VP (VP (VBN inhibited) (NP (-NONE- *-66)) (PP (IN by) (NP-LGS (NNS glucocorticoids))) (PP (IN in) (NP (DT the) (NP-COOD (NP (NN C)) (CC and) (NP (NN AIDS-C))) (NNS groups)))) (-LRB- -LRB-) (NP (NP (NP (QP (RB approximately) (CD 80)) (NN %)) (NP (NN inhibition))) (PP (IN in) (NP (DT both) (NNS groups)))) (-RRB- -RRB-))) (: ;)) (S (NP-SBJ-67 (DT the) (NN effect)) (VP (VBD was) (VP (VBN reversed) (NP (-NONE- *-67)) (PP (IN by) (NP-LGS (DT the) (NN receptor) (NN antagonist) (NN RU-38486))))) (. .)))
(S (PP (IN By) (NP (NN contrast))) (, ,) (NP-SBJ-68 (NNS glucocorticoids)) (VP (VBD failed) (S (NP-SBJ (-NONE- *-68)) (VP (TO to) (VP (VP (VB inhibit) (NP (NP (NN IFNalpha) (NN production)) (PP (IN from) (NP (NN AIDS-GR) (NNS monocytes))))) (-LRB- -LRB-) (NP (NP (QP (RB approximately) (CD 20)) (NN %)) (NP (NN inhibition))) (-RRB- -RRB-))))) (. .))
(S (PP (IN In) (NP (NN conclusion))) (, ,) (NP-SBJ (NP (JJ elevated) (NN IFN) (NN alpha) (NNS levels)) (PP (IN in) (NP (NN AIDS-GR)))) (VP (MD may) (VP (VB be) (PP-PRD (JJ due) (TO to) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NP (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN cortisol))) (PP (IN on) (NP (NN IFN) (NN alpha) (NN production))))) (PP (IN due) (TO to) (NP (NP (JJ cortisol) (NN resistance)) (PP (IN in) (NP (NNS monocytes))))))))) (. .))
